{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:55:25Z","timestamp":1787025325486,"version":"build-2736575974"},"reference-count":89,"publisher":"S.C. JURNALUL PENTRU MEDICINA SI VIATA S.R.L","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JMedLife"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.25122\/jml-2025-0104","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T13:59:29Z","timestamp":1763387969000},"page":"536-544","source":"Crossref","is-referenced-by-count":5,"title":["Beyond the bone marrow: a review of therapeutic approaches for extramedullary disease in multiple myeloma and the significance of MRD assessment"],"prefix":"10.25122","volume":"18","author":[{"given":"Horia","family":"Bumbea","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Bone Marrow Transplantation Unit, Emergency University Hospital, Bucharest, Romania","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Scientific Research Methodology and Hematology, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Diaconescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Bone Marrow Transplantation Unit, Emergency University Hospital, Bucharest, Romania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Scientific Research Methodology and Hematology, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan Sebastian","family":"Soare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Bone Marrow Transplantation Unit, Emergency University Hospital, Bucharest, Romania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Scientific Research Methodology and Hematology, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina Elena","family":"Marinescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Bone Marrow Transplantation Unit, Emergency University Hospital, Bucharest, Romania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Scientific Research Methodology and Hematology, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgiana Elena","family":"Ene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Bone Marrow Transplantation Unit, Emergency University Hospital, Bucharest, Romania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10755","reference":[{"issue":"3","key":"ref1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F","year":"2021","unstructured":"1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F, Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries, CA Cancer J Clin, 2021;71(3):209-249","journal-title":"CA Cancer J Clin"},{"issue":"9","key":"ref2","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/s41408-021-00527-y","article-title":"Extramedullary disease in multiple myeloma","volume":"11","author":"Bansal R, Rakshit S, Kumar S","year":"2021","unstructured":"2. Bansal R, Rakshit S, Kumar S, Extramedullary disease in multiple myeloma, Blood Cancer J, 2021;11(9):161","journal-title":"Blood Cancer J"},{"issue":"1","key":"ref3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41375-019-0660-0","article-title":"Extramedullary multiple myeloma","volume":"34","author":"Bhutani M, Foureau DM, Atrash S, Voorhees PM, Usmani SZ","year":"2020","unstructured":"3. Bhutani M, Foureau DM, Atrash S, Voorhees PM, Usmani SZ, Extramedullary multiple myeloma, Leukemia, 2020;34(1):1-20","journal-title":"Leukemia"},{"issue":"20","key":"ref4","doi-asserted-by":"publisher","first-page":"3085","DOI":"10.1182\/blood-2014-11-568923","article-title":"Treatment options for relapsed and refractory multiple myeloma","volume":"125","author":"Nooka AK, Kastritis E, Dimopoulos MA, Lonial S","year":"2015","unstructured":"4. Nooka AK, Kastritis E, Dimopoulos MA, Lonial S, Treatment options for relapsed and refractory multiple myeloma, Blood, 2015;125(20):3085-99","journal-title":"Blood"},{"issue":"2","key":"ref5","doi-asserted-by":"publisher","first-page":"8396","DOI":"10.4081\/hr.2020.8396","article-title":"Surgery results in low relapse and progression rates in extramedullary plasmacytoma of the head and neck: A case cohort and review of the literature","volume":"12","author":"Skerget M, Dovsak T, Kos G, Zver S","year":"2020","unstructured":"5. Skerget M, Dovsak T, Kos G, Zver S, Surgery results in low relapse and progression rates in extramedullary plasmacytoma of the head and neck: A case cohort and review of the literature, Hematol Rep, 2020;12(2):8396","journal-title":"Hematol Rep"},{"issue":"11","key":"ref6","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1016\/j.bbmt.2019.07.004","article-title":"Tandem Autologous Stem Cell Transplantation Improves Outcomes in Newly Diagnosed Multiple Myeloma with Extramedullary Disease and High-Risk Cytogenetics: A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation","volume":"25","author":"Gagelmann N, Eikema DJ, Koster L, Caillot D, Pioltelli P, Lleonart JB","year":"2019","unstructured":"6. Gagelmann N, Eikema DJ, Koster L, Caillot D, Pioltelli P, Lleonart JB, Tandem Autologous Stem Cell Transplantation Improves Outcomes in Newly Diagnosed Multiple Myeloma with Extramedullary Disease and High-Risk Cytogenetics: A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation, Biology of Blood and Marrow Transplantation, 2019;25(11):2134-42","journal-title":"Biology of Blood and Marrow Transplantation"},{"issue":"28","key":"ref7","doi-asserted-by":"publisher","first-page":"3805","DOI":"10.1200\/JCO.2011.34.9290","article-title":"Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramullary spread, and treatment approach","volume":"29","author":"Blad\u00e9 J, Fern\u00e1ndez de Larrea C, Rosi\u00f1ol L, Cibeira MT, Jim\u00e9nez R, Powles R","year":"2011","unstructured":"7. Blad\u00e9 J, Fern\u00e1ndez de Larrea C, Rosi\u00f1ol L, Cibeira MT, Jim\u00e9nez R, Powles R, Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramullary spread, and treatment approach, J Clin Oncol, 2011;29(28):3805-12","journal-title":"J Clin Oncol"},{"issue":"2","key":"ref8","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1093\/annonc\/mdp329","article-title":"Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients","volume":"21","author":"Varettoni M, Corso A, Pica G, Mangiacavalli S, Pascutto C, Lazzarino M","year":"2010","unstructured":"8. Varettoni M, Corso A, Pica G, Mangiacavalli S, Pascutto C, Lazzarino M, Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients, Ann Oncol, 2010;21(2):325-30","journal-title":"Ann Oncol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"895765","DOI":"10.1100\/2012\/895765","article-title":"A review for solitary plasmacytoma of bone and extramedullary plasmacytoma","volume":"2012","author":"Kilciksiz S, Karakoyun-Celik O, Agaoglu FY, Haydaroglu A","year":"2012","unstructured":"9. Kilciksiz S, Karakoyun-Celik O, Agaoglu FY, Haydaroglu A, A review for solitary plasmacytoma of bone and extramedullary plasmacytoma, ScientificWorldJournal, 2012;2012895765","journal-title":"ScientificWorldJournal"},{"issue":"1","key":"ref10","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1080\/16078454.2021.2005310","article-title":"Research progress on treatment of extramedullary multiple myeloma","volume":"26","author":"Chen Y, Tao Shandong, Zheng Xinqi, Shi Yuye, Zhang Lijuan, Chen Kankan","year":"2021","unstructured":"10. Chen Y, Tao Shandong, Zheng Xinqi, Shi Yuye, Zhang Lijuan, Chen Kankan, Research progress on treatment of extramedullary multiple myeloma, Hematology, 2021;26(1):985-94","journal-title":"Hematology"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"e407","DOI":"10.1200\/EDBK_159074","article-title":"The Role of Imaging in the Treatment of Patients With Multiple Myeloma in 2016","volume":"35","author":"Terpos E, Dimopoulos MA, Moulopoulos LA","year":"2016","unstructured":"11. Terpos E, Dimopoulos MA, Moulopoulos LA, The Role of Imaging in the Treatment of Patients With Multiple Myeloma in 2016, Am Soc Clin Oncol Educ Book, 2016;35e407-417","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"3","key":"ref12","doi-asserted-by":"publisher","first-page":"182","DOI":"10.3390\/curroncol32030182","article-title":"Extramedullary Multiple Myeloma: Challenges and Opportunities","volume":"32","author":"Ho M, Paruzzo L, Minehart J, Nabar N, Noll JH, Luo T","year":"2025","unstructured":"12. Ho M, Paruzzo L, Minehart J, Nabar N, Noll JH, Luo T, Extramedullary Multiple Myeloma: Challenges and Opportunities, Current Oncology, 2025;32(3):182","journal-title":"Current Oncology"},{"issue":"5","key":"ref13","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1046\/j.1365-2141.2003.04355.x","article-title":"Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group","volume":"121","author":"International Myeloma Working Group","year":"2003","unstructured":"13. International Myeloma Working Group, Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group, Br J Haematol, 2003;121(5):749-57","journal-title":"Br J Haematol"},{"issue":"6","key":"ref14","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1182\/blood.V96.6.2037","article-title":"Solitary plasmacytoma of bone and asymptomatic multiple myeloma","volume":"96","author":"Dimopoulos MA, Moulopoulos LA, Maniatis A, Alexanian R","year":"2000","unstructured":"14. Dimopoulos MA, Moulopoulos LA, Maniatis A, Alexanian R, Solitary plasmacytoma of bone and asymptomatic multiple myeloma, Blood, 2000;96(6):2037-44","journal-title":"Blood"},{"issue":"3","key":"ref15","doi-asserted-by":"publisher","first-page":"e11760","DOI":"10.5812\/iranjradiol.11760v2","article-title":"Non Secretory Multiple Myeloma With Extensive Extramedullary Plasmacytoma: A Diagnostic Dilemma","volume":"12","author":"Low SF, Mohd Tap NH, Kew TY, Ngiu CS, Sridharan R","year":"2015","unstructured":"15. Low SF, Mohd Tap NH, Kew TY, Ngiu CS, Sridharan R, Non Secretory Multiple Myeloma With Extensive Extramedullary Plasmacytoma: A Diagnostic Dilemma, Iran J Radiol, 2015;12(3):e11760","journal-title":"Iran J Radiol"},{"issue":"11","key":"ref16","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1055\/a-0604-2831","article-title":"[Extramedullary Plasmacytoma]","volume":"190","author":"Meyer HJ, Ullrich S, Hamerla G, Surov A","year":"2018","unstructured":"16. Meyer HJ, Ullrich S, Hamerla G, Surov A, [Extramedullary Plasmacytoma], Rofo, 2018;190(11):1006-9","journal-title":"Rofo"},{"issue":"3","key":"ref17","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1111\/j.1365-2141.2004.05199.x","article-title":"Multiple myeloma involving central nervous system: high frequency of chromosome 17p13.1 (p53) deletions","volume":"127","author":"Chang H, Sloan S, Li D, Keith Stewart A","year":"2004","unstructured":"17. Chang H, Sloan S, Li D, Keith Stewart A, Multiple myeloma involving central nervous system: high frequency of chromosome 17p13.1 (p53) deletions, Br J Haematol, 2004;127(3):280-4","journal-title":"Br J Haematol"},{"issue":"4","key":"ref18","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1111\/j.1600-0609.2009.01399.x","article-title":"P53 deletion may drive the clinical evolution and treatment response in multiple myeloma","volume":"84","author":"L\u00f3pez-Anglada L, Guti\u00e9rrez NC, Garc\u00eda JL, Mateos MV, Flores T, San Miguel JF","year":"2010","unstructured":"18. L\u00f3pez-Anglada L, Guti\u00e9rrez NC, Garc\u00eda JL, Mateos MV, Flores T, San Miguel JF, P53 deletion may drive the clinical evolution and treatment response in multiple myeloma, Eur J Haematol, 2010;84(4):359-61","journal-title":"Eur J Haematol"},{"issue":"5","key":"ref19","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.clml.2014.12.013","article-title":"Features of Extramedullary Disease of Multiple Myeloma: High Frequency of P53 Deletion and Poor Survival: A Retrospective Single-Center Study of 834 Cases. Clinical Lymphoma","volume":"15","author":"Deng S, Xu Y, An G, Sui W, Zou D, Zhao Y","year":"2015","unstructured":"19. Deng S, Xu Y, An G, Sui W, Zou D, Zhao Y, Features of Extramedullary Disease of Multiple Myeloma: High Frequency of P53 Deletion and Poor Survival: A Retrospective Single-Center Study of 834 Cases. Clinical Lymphoma, Myeloma and Leukemia, 2015;15(5):286-91","journal-title":"Myeloma and Leukemia"},{"issue":"1","key":"ref20","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/ejh.12688","article-title":"Cytogenetics in multiple myeloma patients progressing into extramedullary disease","volume":"97","author":"Besse L, Sedlarikova L, Greslikova H, Kupska R, Almasi M, Penka M","year":"2016","unstructured":"20. Besse L, Sedlarikova L, Greslikova H, Kupska R, Almasi M, Penka M, Cytogenetics in multiple myeloma patients progressing into extramedullary disease, Eur J Haematol, 2016;97(1):93-100","journal-title":"Eur J Haematol"},{"key":"ref21","article-title":"Radiopaedia","author":"Niknejad MT","unstructured":"21. Niknejad MT, Radiopaedia, Extramedullary plasmacytoma | Radiology Reference Article | Radiopaedia.org, Available from: https:\/\/radiopaedia.org\/articles\/extramedullary-plasmacytoma?lang=us","journal-title":"Extramedullary plasmacytoma | Radiology Reference Article | Radiopaedia.org"},{"issue":"4","key":"ref22","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood.V85.4.863.bloodjournal854863","article-title":"Interleukin-6 in human multiple myeloma","volume":"85","author":"Klein B, Zhang XG, Lu ZY, Bataille R","year":"1995","unstructured":"22. Klein B, Zhang XG, Lu ZY, Bataille R, Interleukin-6 in human multiple myeloma, Blood, 1995;85(4):863-72","journal-title":"Blood"},{"issue":"4","key":"ref23","first-page":"1073","article-title":"Secondary plasma cell leukemia","volume":"53","author":"Rotaru I, G\u0103man G, Dumitrescu D, Foarf\u0103 C","year":"2012","unstructured":"23. Rotaru I, G\u0103man G, Dumitrescu D, Foarf\u0103 C, Secondary plasma cell leukemia, Rom J Morphol Embryol, 2012;53(4):1073-6","journal-title":"Rom J Morphol Embryol"},{"issue":"6","key":"ref24","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1111\/bjh.13383","article-title":"Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantation","volume":"169","author":"Weinstock M, Aljawai Y, Morgan EA, Laubach J, Gannon M, Roccaro AM","year":"2015","unstructured":"24. Weinstock M, Aljawai Y, Morgan EA, Laubach J, Gannon M, Roccaro AM, Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantation, Br J Haematol, 2015;169(6):851-8","journal-title":"Br J Haematol"},{"issue":"3","key":"ref25","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1111\/ejh.12907","article-title":"Incidence, characteristics, and outcome of solitary plasmacytoma and plasma cell leukemia. Population-based data from the Swedish Myeloma Register","volume":"99","author":"Nahi H, Genell A, W\u00e5linder G, Uttervall K, Juliusson G, Karin F","year":"2017","unstructured":"25. Nahi H, Genell A, W\u00e5linder G, Uttervall K, Juliusson G, Karin F, Incidence, characteristics, and outcome of solitary plasmacytoma and plasma cell leukemia. Population-based data from the Swedish Myeloma Register, Eur J Haematol, 2017;99(3):216-22","journal-title":"Eur J Haematol"},{"issue":"3","key":"ref26","doi-asserted-by":"publisher","first-page":"e137","DOI":"10.1016\/S2468-2667(18)30267-6","article-title":"Emerging cancer trends among young adults in the USA: analysis of a population-based cancer registry","volume":"4","author":"Sung H, Siegel RL, Rosenberg PS, Jemal A","year":"2019","unstructured":"26. Sung H, Siegel RL, Rosenberg PS, Jemal A, Emerging cancer trends among young adults in the USA: analysis of a population-based cancer registry, Lancet Public Health, 2019;4(3):e137-47","journal-title":"Lancet Public Health"},{"issue":"11","key":"ref27","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.1002\/cncr.20652","article-title":"Incidence of multiple myeloma in Olmsted County, Minnesota: Trend over 6 decades","volume":"101","author":"Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Melton LJ","year":"2004","unstructured":"27. Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Melton LJ, Incidence of multiple myeloma in Olmsted County, Minnesota: Trend over 6 decades, Cancer, 2004;101(11):2667-74","journal-title":"Cancer"},{"key":"ref28","article-title":"Plasmacytoma","author":"Iqbal QUA, Majid HJ","year":"2025","unstructured":"28. Iqbal QUA, Majid HJ, Plasmacytoma, StatPearls [Internet], Treasure Island (FL):StatPearls Publishing, 2025;Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK573076\/","journal-title":"StatPearls [Internet]"},{"issue":"5","key":"ref29","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.3324\/haematol.2024.286409","article-title":"Bone-independent extramedullary disease is associated with inferior overall survival in multiple myeloma patients: a single-center, real-world experience","volume":"110","author":"Xu K, Agbuduwe C, Kanellias N, Wilson W, McMillan A, Papanikolaou X","year":"2025","unstructured":"29. Xu K, Agbuduwe C, Kanellias N, Wilson W, McMillan A, Papanikolaou X, Bone-independent extramedullary disease is associated with inferior overall survival in multiple myeloma patients: a single-center, real-world experience, Haematologica, 2025;110(5):1182-6","journal-title":"Haematologica"},{"issue":"1","key":"ref30","doi-asserted-by":"publisher","first-page":"193","DOI":"10.3324\/haematol.2019.219139","article-title":"Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs","volume":"105","author":"Montefusco V, Gay F, Spada S, De Paoli L, Di Raimondo F, Ribolla R","year":"2020","unstructured":"30. Montefusco V, Gay F, Spada S, De Paoli L, Di Raimondo F, Ribolla R, Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs, Haematologica, 2020;105(1):193-200","journal-title":"Haematologica"},{"issue":"7","key":"ref31","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1182\/bloodadvances.2024013355","article-title":"Solitary plasmacytoma: single-institution experience, and systematic review and meta-analysis of clinical outcomes","volume":"9","author":"Charalampous C, Claveau JS, Kapoor P, Binder M, Buadi FK, Cook J","year":"2025","unstructured":"31. Charalampous C, Claveau JS, Kapoor P, Binder M, Buadi FK, Cook J, Solitary plasmacytoma: single-institution experience, and systematic review and meta-analysis of clinical outcomes, Blood Adv, 2025;9(7):1559-70","journal-title":"Blood Adv"},{"issue":"3","key":"ref32","doi-asserted-by":"publisher","first-page":"e70151","DOI":"10.1002\/cnr2.70151","article-title":"Exploration of the Prognostic Markers of Multiple Myeloma Based on Cuproptosis-Related Genes","volume":"8","author":"Gao XH, Yuan J, Zhang XX, Wang RC, Yang J, Li Y","year":"2025","unstructured":"32. Gao XH, Yuan J, Zhang XX, Wang RC, Yang J, Li Y, Exploration of the Prognostic Markers of Multiple Myeloma Based on Cuproptosis-Related Genes, Cancer Rep (Hoboken), 2025;8(3):e70151","journal-title":"Cancer Rep (Hoboken)"},{"issue":"2","key":"ref33","doi-asserted-by":"publisher","first-page":"e32647","DOI":"10.1097\/MD.0000000000032647","article-title":"Diagnosis and management of extramedullary plasmacytoma in nasal cavity: Clinical experience and literature review","volume":"102","author":"Hu H, Hu X, Hu G, Li D, Cai J","year":"2023","unstructured":"33. Hu H, Hu X, Hu G, Li D, Cai J, Diagnosis and management of extramedullary plasmacytoma in nasal cavity: Clinical experience and literature review, Medicine (Baltimore), 2023;102(2):e32647","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"ref34","doi-asserted-by":"publisher","first-page":"e019758","DOI":"10.1136\/bmjopen-2017-019758","article-title":"Quantifying intervals to diagnosis in myeloma: a systematic review and meta-analysis","volume":"8","author":"Koshiaris C, Oke J, Abel L, Nicholson BD, Ramasamy K, Van den Bruel A","year":"2018","unstructured":"34. Koshiaris C, Oke J, Abel L, Nicholson BD, Ramasamy K, Van den Bruel A, Quantifying intervals to diagnosis in myeloma: a systematic review and meta-analysis, BMJ Open, 2018;8(6):e019758","journal-title":"BMJ Open"},{"issue":"1","key":"ref35","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13045-017-0549-1","article-title":"Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel","volume":"11","author":"Caers J, Paiva B, Zamagni E, Leleu X, Blad\u00e9 J, Kristinsson SY","year":"2018","unstructured":"35. Caers J, Paiva B, Zamagni E, Leleu X, Blad\u00e9 J, Kristinsson SY, Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel, J Hematol Oncol, 2018;11(1):10","journal-title":"J Hematol Oncol"},{"issue":"4","key":"ref36","doi-asserted-by":"publisher","first-page":"255","DOI":"10.4103\/jpgm.JPGM_296_18","article-title":"Plasmacytoma of the mesentery","volume":"64","author":"Thambi S, Nair S, Benson R","year":"2018","unstructured":"36. Thambi S, Nair S, Benson R, Plasmacytoma of the mesentery, J Postgrad Med, 2018;64(4):255-7","journal-title":"J Postgrad Med"},{"issue":"12","key":"ref37","first-page":"81","article-title":"Primary isolated extramedullary plasmacytoma of mesentry: a rare case report","author":"Galhotra R, Saggar K, Gupta K, Singh P","year":"2012","unstructured":"37. Galhotra R, Saggar K, Gupta K, Singh P, Primary isolated extramedullary plasmacytoma of mesentry: a rare case report, Gulf J Oncolog, 2012;(12):81-4","journal-title":"Gulf J Oncolog"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"5901503","DOI":"10.1155\/2017\/5901503","article-title":"Solitary Plasmacytoma of the Mesentery: A Systematic Clinician\u2019s Diagnosis","volume":"2017","author":"Mitropoulou G, Zizi-Sermpetzoglou A, Moschouris H, Kountourogiannis A, Myoteri D, Dellaportas D","year":"2017","unstructured":"38. Mitropoulou G, Zizi-Sermpetzoglou A, Moschouris H, Kountourogiannis A, Myoteri D, Dellaportas D, Solitary Plasmacytoma of the Mesentery: A Systematic Clinician\u2019s Diagnosis, Case Rep Oncol Med, 2017;20175901503","journal-title":"Case Rep Oncol Med"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"92","DOI":"10.11604\/pamj.2019.34.92.20089","article-title":"[Solitary plasmacytoma of the lung treated with radiotherapy: case study and literature review]","volume":"34","author":"Elmorabit B, Derhem N, Khouchani M","year":"2019","unstructured":"39. Elmorabit B, Derhem N, Khouchani M, [Solitary plasmacytoma of the lung treated with radiotherapy: case study and literature review], Pan Afr Med J, 2019;3492","journal-title":"Pan Afr Med J"},{"key":"ref40","first-page":"443","article-title":"Myeloma: Biology and Management","author":"Jackson GH, Malpas JS, Bergsagel DE, Kyle RA, Anderson KC","year":"2003","unstructured":"40. Jackson GH, Malpas JS, Bergsagel DE, Kyle RA, Anderson KC, Myeloma: Biology and Management, Saunders, 2003;443pages. ISBN: 0721600069. Clin Oncol (R Coll Radiol). 2004 Sep; 16(6):441","journal-title":"Saunders"},{"issue":"5","key":"ref41","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1038\/leu.2015.356","article-title":"Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group","volume":"30","author":"Laubach J, Garderet L, Mahindra A, Gahrton G, Caers J, Sezer O","year":"2016","unstructured":"41. Laubach J, Garderet L, Mahindra A, Gahrton G, Caers J, Sezer O, Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group, Leukemia, 2016;30(5):1005-17","journal-title":"Leukemia"},{"issue":"8","key":"ref42","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1182\/blood-2015-07-635383","article-title":"How I treat extramedullary myeloma","volume":"127","author":"Touzeau C, Moreau P","year":"2016","unstructured":"42. Touzeau C, Moreau P, How I treat extramedullary myeloma, Blood, 2016;127(8):971-6","journal-title":"Blood"},{"issue":"5","key":"ref43","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1182\/blood-2012-01-405977","article-title":"Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides","volume":"120","author":"Egan JB, Shi CX, Tembe W, Christoforides A, Kurdoglu A, Sinari S","year":"2012","unstructured":"43. Egan JB, Shi CX, Tembe W, Christoforides A, Kurdoglu A, Sinari S, Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides, Blood, 2012;120(5):1060-6","journal-title":"Blood"},{"issue":"7","key":"ref44","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.3390\/cancers17071081","article-title":"Unveiling Extramedullary Myeloma Immune Microenvironment: A Systematic Review","volume":"17","author":"Boulogeorgou K, Papaioannou M, Chatzileontiadou S, Georgiou E, Fola A, Tzorakoleftheraki SE, Hatjiharissi E, Koletsa T","year":"2025","unstructured":"44. Boulogeorgou K, Papaioannou M, Chatzileontiadou S, Georgiou E, Fola A, Tzorakoleftheraki SE, Hatjiharissi E, Koletsa T, Unveiling Extramedullary Myeloma Immune Microenvironment: A Systematic Review, Cancers (Basel), 2025;17(7):1081","journal-title":"Cancers (Basel)"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1016\/j.rx.2020.07.006","article-title":"Evaluation of Extramedullary Plasmacytoma of the Larynx with Radiologic and Histopathological Findings","author":"Tanrivermis Sayit A, Elmali M, G\u00fcn S","year":"2020","unstructured":"45. Tanrivermis Sayit A, Elmali M, G\u00fcn S, Evaluation of Extramedullary Plasmacytoma of the Larynx with Radiologic and Histopathological Findings, Radiologia (Engl Ed), 2020;S00338338(20)30121-1","journal-title":"Radiologia (Engl Ed)"},{"issue":"4","key":"ref46","doi-asserted-by":"publisher","first-page":"e206","DOI":"10.1016\/S1470-2045(17)30189-4","article-title":"Role of 18F-FDG PET\/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group","volume":"18","author":"Cavo M, Terpos E, Nanni C, Moreau P, Lentzsch S, Zweegman S","year":"2017","unstructured":"46. Cavo M, Terpos E, Nanni C, Moreau P, Lentzsch S, Zweegman S, Role of 18F-FDG PET\/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group, Lancet Oncol, 2017;18(4):e206-17","journal-title":"Lancet Oncol"},{"issue":"12","key":"ref47","doi-asserted-by":"publisher","first-page":"3029","DOI":"10.3324\/haematol.2021.279797","article-title":"Images from the Haematologica Atlas of Hematologic Cytology: hemophagocytic syndrome","volume":"106","author":"Invernizzi R","year":"2021","unstructured":"47. Invernizzi R, Images from the Haematologica Atlas of Hematologic Cytology: hemophagocytic syndrome, Haematologica, 2021;106(12):3029-3029","journal-title":"Haematologica"},{"issue":"4","key":"ref48","doi-asserted-by":"publisher","first-page":"803","DOI":"10.2214\/AJR.13.10856","article-title":"MRI features of extramedullary myeloma","volume":"202","author":"Tirumani SH, Shinagare AB, Jagannathan JP, Krajewski KM, Munshi NC, Ramaiya NH","year":"2014","unstructured":"48. Tirumani SH, Shinagare AB, Jagannathan JP, Krajewski KM, Munshi NC, Ramaiya NH, MRI features of extramedullary myeloma, AJR Am J Roentgenol, 2014;202(4):803-10","journal-title":"AJR Am J Roentgenol"},{"issue":"1169","key":"ref49","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1093\/bjr\/tqaf031","article-title":"Head and neck manifestations of extramedullary plasmacytomas and their differential diagnoses: a pictorial review","volume":"98","author":"Wilkinson S, Jawad S, Kowa XY","year":"2025","unstructured":"49. Wilkinson S, Jawad S, Kowa XY, Head and neck manifestations of extramedullary plasmacytomas and their differential diagnoses: a pictorial review, Br J Radiol, 2025;98(1169):640-649","journal-title":"Br J Radiol"},{"key":"ref50","article-title":"Radiopaedia","author":"Yap K","unstructured":"50. Yap K, Radiopaedia, Multiple myeloma | Radiology Reference Article | Radiopaedia.org, Available from: https:\/\/radiopaedia.org\/articles\/multiple-myeloma-1?lang=us","journal-title":"Multiple myeloma | Radiology Reference Article | Radiopaedia.org"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"7583","DOI":"10.2147\/OTT.S122241","article-title":"Non-secretory multiple myeloma: from biology to clinical management","volume":"9","author":"Dupuis MM, Tuchman SA","year":"2016","unstructured":"51. Dupuis MM, Tuchman SA, Non-secretory multiple myeloma: from biology to clinical management, Onco Targets Ther, 2016;97583-90","journal-title":"Onco Targets Ther"},{"issue":"17","key":"ref52","doi-asserted-by":"publisher","first-page":"7381","DOI":"10.18632\/oncotarget.229054","article-title":"18 FDG-PET\/CT for prognostic stratification of patients with multiple myeloma relapse after stem cell transplantation","volume":"5","author":"Lapa C, L\u00fcckerath K, Malzahn U, Samnick S, Einsele H, Buck AK","year":"2014","unstructured":"52. Lapa C, L\u00fcckerath K, Malzahn U, Samnick S, Einsele H, Buck AK, 18 FDG-PET\/CT for prognostic stratification of patients with multiple myeloma relapse after stem cell transplantation, Oncotarget, 2014;5(17):7381-91","journal-title":"Oncotarget"},{"issue":"4","key":"ref53","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.beha.2018.10.003","article-title":"Imaging in multiple myeloma: How?","volume":"31","author":"Zamagni E, Tacchetti P, Cavo M","year":"2018","unstructured":"53. Zamagni E, Tacchetti P, Cavo M, Imaging in multiple myeloma: How?, When? Best Pract Res Clin Haematol, 2018;31(4):319-30","journal-title":"When? Best Pract Res Clin Haematol"},{"issue":"6","key":"ref54","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1111\/j.1365-2141.2004.04834.x","article-title":"Guidelines on the diagnosis and management of solitary plasmacytoma of bone and solitary extramedullary plasmacytoma","volume":"124","author":"Soutar R, Lucraft H, Jackson G, Reece A, Bird J, Low E, Samson D, Guidelines Working Group of the UK Myeloma Forum; British Committee for Standards in Haematology; British Society for Haematology","year":"2004","unstructured":"54. Soutar R, Lucraft H, Jackson G, Reece A, Bird J, Low E, Samson D, Guidelines Working Group of the UK Myeloma Forum; British Committee for Standards in Haematology; British Society for Haematology, Guidelines on the diagnosis and management of solitary plasmacytoma of bone and solitary extramedullary plasmacytoma, Br J Haematol, 2004;124(6):717-26","journal-title":"Br J Haematol"},{"issue":"1","key":"ref55","first-page":"101","article-title":"Radiotherapy in the management of plasma cell tumors","volume":"14","author":"Hu K, Yahalom J","year":"2000","unstructured":"55. Hu K, Yahalom J, Radiotherapy in the management of plasma cell tumors, Oncology (Williston Park), 2000;14(1):101-8111; discussion 111-2, 115","journal-title":"Oncology (Williston Park)"},{"issue":"11","key":"ref56","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1007\/s00277-012-1510-6","article-title":"Radiotherapy for solitary plasmacytoma of bone and soft tissue: outcomes and prognostic factors","volume":"91","author":"Suh YG, Suh CO, Kim JS, Kim SJ, Pyun HO, Cho J","year":"2012","unstructured":"56. Suh YG, Suh CO, Kim JS, Kim SJ, Pyun HO, Cho J, Radiotherapy for solitary plasmacytoma of bone and soft tissue: outcomes and prognostic factors, Ann Hematol, 2012;91(11):1785-93","journal-title":"Ann Hematol"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"356","DOI":"10.25259\/SNI_442_2021","article-title":"Recurrent solitary bone plasmacytoma: A case report","volume":"12","author":"Sakhrekar R, Khurjekar K, Hadgaonkar S, Bhilare P, Sancheti P, Shyam A","year":"2021","unstructured":"57. Sakhrekar R, Khurjekar K, Hadgaonkar S, Bhilare P, Sancheti P, Shyam A, Recurrent solitary bone plasmacytoma: A case report, Surg Neurol Int, 2021;12356","journal-title":"Surg Neurol Int"},{"issue":"6","key":"ref58","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1002\/1097-0142(19920315)69:6<1513::aid-cncr2820690633>3.0.co;2-x","article-title":"Plasmacytoma","volume":"69","author":"Holland J, Trenkner DA, Wasserman TH, Fineberg B","year":"1992","unstructured":"58. Holland J, Trenkner DA, Wasserman TH, Fineberg B, Plasmacytoma, Treatment results and conversion to myeloma. Cancer, 1992;69(6):1513-7","journal-title":"Treatment results and conversion to myeloma. Cancer"},{"issue":"3","key":"ref59","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41408-022-00643-3","article-title":"Extramedullary disease in multiple myeloma: a systematic literature review","volume":"12","author":"Blad\u00e9 J, Beksac M, Caers J, Jurczyszyn A, von Lilienfeld-Toal M, Moreau P","year":"2022","unstructured":"59. Blad\u00e9 J, Beksac M, Caers J, Jurczyszyn A, von Lilienfeld-Toal M, Moreau P, Extramedullary disease in multiple myeloma: a systematic literature review, Blood Cancer J, 2022;12(3):45","journal-title":"Blood Cancer J"},{"issue":"10","key":"ref60","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1038\/bmt.2017.165","article-title":"Multiple myeloma with extramedullary disease: impact of autologous stem cell transplantation on outcome","volume":"52","author":"Kumar L, Gogi R, Patel AK, Mookerjee A, Sahoo RK, Malik PS","year":"2017","unstructured":"60. Kumar L, Gogi R, Patel AK, Mookerjee A, Sahoo RK, Malik PS, Multiple myeloma with extramedullary disease: impact of autologous stem cell transplantation on outcome, Bone Marrow Transplant, 2017;52(10):1473-5","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"ref61","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1007\/s00277-014-2023-2","article-title":"The lymphoma-like polychemotherapy regimen \u201cDexa-BEAM\u201d in advanced and extramedullary multiple myeloma","volume":"93","author":"Rasche L, Strifler S, Duell J, Rosenwald A, Buck A, Maeder U","year":"2014","unstructured":"61. Rasche L, Strifler S, Duell J, Rosenwald A, Buck A, Maeder U, The lymphoma-like polychemotherapy regimen \u201cDexa-BEAM\u201d in advanced and extramedullary multiple myeloma, Ann Hematol, 2014;93(7):1207-14","journal-title":"Ann Hematol"},{"issue":"3","key":"ref62","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1111\/bjh.17338","article-title":"Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations","volume":"194","author":"Rosi\u00f1ol L, Beksac M, Zamagni E, Van de Donk NWCJ, Anderson KC, Badros A","year":"2021","unstructured":"62. Rosi\u00f1ol L, Beksac M, Zamagni E, Van de Donk NWCJ, Anderson KC, Badros A, Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations, Br J Haematol, 2021;194(3):496-507","journal-title":"Br J Haematol"},{"issue":"4","key":"ref63","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.3390\/cancers12041035","article-title":"Carfilzomib Based Treatment Strategies in the Management of Relapsed\/Refractory Multiple Myeloma with Extramedullary Disease","volume":"12","author":"Zhou X, Fl\u00fcchter P, Nickel K, Meckel K, Messerschmidt J, B\u00f6ckle D","year":"2020","unstructured":"63. Zhou X, Fl\u00fcchter P, Nickel K, Meckel K, Messerschmidt J, B\u00f6ckle D, Carfilzomib Based Treatment Strategies in the Management of Relapsed\/Refractory Multiple Myeloma with Extramedullary Disease, Cancers (Basel), 2020;12(4):1035","journal-title":"Cancers (Basel)"},{"issue":"6","key":"ref64","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1002\/cncr.26447","article-title":"Extramedullary intracranial localization of multiple myeloma and treatment with novel agents: A retrospective survey of 50 patients","volume":"118","author":"Gozzetti A, Cerase A, Lotti F, Rossi D, Palumbo A, Petrucci MT","year":"2012","unstructured":"64. Gozzetti A, Cerase A, Lotti F, Rossi D, Palumbo A, Petrucci MT, Extramedullary intracranial localization of multiple myeloma and treatment with novel agents: A retrospective survey of 50 patients, Cancer, 2012;118(6):1574-84","journal-title":"Cancer"},{"issue":"7","key":"ref65","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.3324\/haematol.2020.248518","article-title":"Multiple myeloma with central nervous system relapse","volume":"105","author":"Egan PA, Elder PT, Deighan WI, O\u2019Connor SJM, Alexander HD","year":"2020","unstructured":"65. Egan PA, Elder PT, Deighan WI, O\u2019Connor SJM, Alexander HD, Multiple myeloma with central nervous system relapse, Haematologica, 2020;105(7):1780-90","journal-title":"Haematologica"},{"issue":"2","key":"ref66","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/s41375-024-02154-5","article-title":"Real-world analysis of teclistamab in 123 RRMM patients from Germany","volume":"38","author":"Riedhammer C, Bassermann F, Besemer B, Bewarder M, Brunner F, Carpinteiro A","year":"2024","unstructured":"66. Riedhammer C, Bassermann F, Besemer B, Bewarder M, Brunner F, Carpinteiro A, Real-world analysis of teclistamab in 123 RRMM patients from Germany, Leukemia, 2024;38(2):365-71","journal-title":"Leukemia"},{"issue":"6","key":"ref67","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in Relapsed or Refractory Multiple Myeloma","volume":"387","author":"Moreau P, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, Oriol A","year":"2022","unstructured":"67. Moreau P, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, Oriol A, Teclistamab in Relapsed or Refractory Multiple Myeloma, N Engl J Med, 2022;387(6):495-505","journal-title":"N Engl J Med"},{"issue":"Suppl","key":"ref68","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000967672.15362.d7","article-title":"S190: FIRST RESULTS FROM THE REDIRECTT-1 STUDY WITH TECLISTAMAB (TEC) + TALQUETAMAB (TAL) SIMULTANEOUSLY TARGETING BCMA AND GPRC5D IN PATIENTS (PTS) WITH RELAPSED\/REFRACTORY MULTIPLE MYELOMA (RRMM)","volume":"7","author":"Mateos MV, Morillo D, Gatt M, Sebag M, Kim K, Min CK, Oriol A, Ocio E, Yoon SS, Cohen Y, Chu M, Rodr\u00edguez-Otero P, Avivi I, Guo Y, Krevvata M, Peterson M, Beelen M, Vanak J, Banerjee A, Magen H","year":"2023","unstructured":"68. Mateos MV, Morillo D, Gatt M, Sebag M, Kim K, Min CK, Oriol A, Ocio E, Yoon SS, Cohen Y, Chu M, Rodr\u00edguez-Otero P, Avivi I, Guo Y, Krevvata M, Peterson M, Beelen M, Vanak J, Banerjee A, Magen H, S190: FIRST RESULTS FROM THE REDIRECTT-1 STUDY WITH TECLISTAMAB (TEC) + TALQUETAMAB (TAL) SIMULTANEOUSLY TARGETING BCMA AND GPRC5D IN PATIENTS (PTS) WITH RELAPSED\/REFRACTORY MULTIPLE MYELOMA (RRMM), Hemasphere, 2023;7(Suppl):e15362d7","journal-title":"Hemasphere"},{"issue":"3","key":"ref69","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1111\/j.1365-2141.2009.07864.x","article-title":"TP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3","volume":"147","author":"Shaughnessy JD, Zhou Y, Haessler J, van Rhee F, Anaissie E, Nair B","year":"2009","unstructured":"69. Shaughnessy JD, Zhou Y, Haessler J, van Rhee F, Anaissie E, Nair B, TP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3, Br J Haematol, 2009;147(3):347-51","journal-title":"Br J Haematol"},{"issue":"4","key":"ref70","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1182\/blood-2015-08-666537","article-title":"Sequential vs alternating administration of VMP and Rd in elderly patients with newly diagnosed MM","volume":"127","author":"Mateos MV, Mart\u00ednez-L\u00f3pez J, Hern\u00e1ndez MT, Ocio EM, Rosi\u00f1ol L, Mart\u00ednez R","year":"2016","unstructured":"70. Mateos MV, Mart\u00ednez-L\u00f3pez J, Hern\u00e1ndez MT, Ocio EM, Rosi\u00f1ol L, Mart\u00ednez R, Sequential vs alternating administration of VMP and Rd in elderly patients with newly diagnosed MM, Blood, 2016;127(4):420-5","journal-title":"Blood"},{"issue":"4","key":"ref71","first-page":"266","article-title":"Efficacy of bortezomib in systemic extramedullary localizations of multiple myeloma","volume":"10","author":"Federico V, Breccia M, Petrucci MT, Loglisci G, Mansueto G, Mercanti C","year":"2012","unstructured":"71. Federico V, Breccia M, Petrucci MT, Loglisci G, Mansueto G, Mercanti C, Efficacy of bortezomib in systemic extramedullary localizations of multiple myeloma, Clin Adv Hematol Oncol, 2012;10(4):266-8","journal-title":"Clin Adv Hematol Oncol"},{"issue":"1","key":"ref72","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41408-024-01139-y","article-title":"Bispecific antibodies in the treatment of multiple myeloma","volume":"14","author":"Devasia AJ, Chari A, Lancman G","year":"2024","unstructured":"72. Devasia AJ, Chari A, Lancman G, Bispecific antibodies in the treatment of multiple myeloma, Blood Cancer J, 2024;14(1):158","journal-title":"Blood Cancer J"},{"issue":"5","key":"ref73","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.hoc.2014.06.004","article-title":"Treatment of transplant-eligible patients with multiple myeloma in 2014","volume":"28","author":"Landau H, Giralt S","year":"2014","unstructured":"73. Landau H, Giralt S, Treatment of transplant-eligible patients with multiple myeloma in 2014, Hematol Oncol Clin North Am, 2014;28(5):815-27","journal-title":"Hematol Oncol Clin North Am"},{"issue":"11","key":"ref74","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.clml.2023.07.010","article-title":"A Meta-Analysis of the Efficacy of Pomalidomide-Based Regimens for the Treatment of Relapsed\/Refractory Multiple Myeloma After Lenalidomide Exposure","volume":"23","author":"Davies FE, Leleu X, Vogel P, Dhanasiri S, Le Nouveau P, Weisel K","year":"2023","unstructured":"74. Davies FE, Leleu X, Vogel P, Dhanasiri S, Le Nouveau P, Weisel K, A Meta-Analysis of the Efficacy of Pomalidomide-Based Regimens for the Treatment of Relapsed\/Refractory Multiple Myeloma After Lenalidomide Exposure, Clin Lymphoma Myeloma Leuk, 2023;23(11):829-837.e1","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"101465","DOI":"10.1016\/j.tranon.2022.101465","article-title":"Advances in the treatment of extramedullary disease in multiple myeloma","volume":"22","author":"Li Y, Sun Z, Qu X","year":"2022","unstructured":"75. Li Y, Sun Z, Qu X, Advances in the treatment of extramedullary disease in multiple myeloma, Transl Oncol, 2022;22101465","journal-title":"Transl Oncol"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"1394048","DOI":"10.3389\/fonc.2024.1394048","article-title":"Bispecific antibodies for the treatment of relapsed\/refractory multiple myeloma: updates and future perspectives","volume":"14","author":"Parrondo RD, Ailawadhi S, Cerchione C","year":"2024","unstructured":"76. Parrondo RD, Ailawadhi S, Cerchione C, Bispecific antibodies for the treatment of relapsed\/refractory multiple myeloma: updates and future perspectives, Front Oncol, 2024;141394048","journal-title":"Front Oncol"},{"issue":"6","key":"ref77","doi-asserted-by":"publisher","first-page":"612","DOI":"10.3892\/ol.2024.14745","article-title":"Efficacy of the CV-MED regimen in treating extramedullary involvement of multiple myeloma: A case report","volume":"28","author":"Gao J, Dong F, Zhang X, Jing H","year":"2024","unstructured":"77. Gao J, Dong F, Zhang X, Jing H, Efficacy of the CV-MED regimen in treating extramedullary involvement of multiple myeloma: A case report, Oncol Lett, 2024;28(6):612","journal-title":"Oncol Lett"},{"issue":"2","key":"ref78","doi-asserted-by":"publisher","first-page":"621","DOI":"10.3324\/haematol.2021.280051","article-title":"Prognostic value of positron emission tomography\/computed tomography in transplant-eligible newly diagnosed multiple myeloma patients from CASSIOPEIA: the CASSIOPET study","volume":"108","author":"Kraeber-Bod\u00e9r\u00e9 F, Zweegman S, Perrot A, Hulin C, Caillot D, Facon T","year":"2023","unstructured":"78. Kraeber-Bod\u00e9r\u00e9 F, Zweegman S, Perrot A, Hulin C, Caillot D, Facon T, Prognostic value of positron emission tomography\/computed tomography in transplant-eligible newly diagnosed multiple myeloma patients from CASSIOPEIA: the CASSIOPET study, Haematologica, 2023;108(2):621-6","journal-title":"Haematologica"},{"issue":"6","key":"ref79","doi-asserted-by":"publisher","DOI":"10.1111\/ecc.12732","article-title":"Standardisation of minimal residual disease in multiple myeloma","volume":"26","author":"Innao V, Allegra A, Russo S, Gerace D, Vaddinelli D, Alonci A","year":"2017","unstructured":"79. Innao V, Allegra A, Russo S, Gerace D, Vaddinelli D, Alonci A, Standardisation of minimal residual disease in multiple myeloma, Eur J Cancer Care (Engl), 2017;26(6):","journal-title":"Eur J Cancer Care (Engl)"},{"issue":"4","key":"ref80","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.cll.2017.08.001","article-title":"Diagnosis of Plasma Cell Dyscrasias and Monitoring of Minimal Residual Disease by Multiparametric Flow Cytometry","volume":"37","author":"Soh KT, Tario JD, Wallace PK","year":"2017","unstructured":"80. Soh KT, Tario JD, Wallace PK, Diagnosis of Plasma Cell Dyscrasias and Monitoring of Minimal Residual Disease by Multiparametric Flow Cytometry, Clin Lab Med, 2017;37(4):821-53","journal-title":"Clin Lab Med"},{"issue":"20","key":"ref81","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1182\/blood-2014-11-568907","article-title":"New criteria for response assessment: role of minimal residual disease in multiple myeloma","volume":"125","author":"Paiva B, van Dongen JJM, Orfao A","year":"2015","unstructured":"81. Paiva B, van Dongen JJM, Orfao A, New criteria for response assessment: role of minimal residual disease in multiple myeloma, Blood, 2015;125(20):3059-68","journal-title":"Blood"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"1057713","DOI":"10.3389\/fonc.2022.1057713","article-title":"\u201cFriends and foes\u201d of multiple myeloma measurable\/minimal residual disease evaluation by next generation flow","volume":"12","author":"Pacelli P, Raspadori D, Bestoso E, Gozzetti A, Bocchia M","year":"2022","unstructured":"82. Pacelli P, Raspadori D, Bestoso E, Gozzetti A, Bocchia M, \u201cFriends and foes\u201d of multiple myeloma measurable\/minimal residual disease evaluation by next generation flow, Front Oncol, 2022;121057713","journal-title":"Front Oncol"},{"issue":"23","key":"ref83","doi-asserted-by":"publisher","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","article-title":"A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma","volume":"4","author":"Munshi NC, Avet-Loiseau H, Anderson KC, Neri P, Paiva B, Samur M","year":"2020","unstructured":"83. Munshi NC, Avet-Loiseau H, Anderson KC, Neri P, Paiva B, Samur M, A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma, Blood Adv, 2020;4(23):5988-99","journal-title":"Blood Adv"},{"key":"ref84","doi-asserted-by":"publisher","first-page":"932852","DOI":"10.3389\/fonc.2022.932852","article-title":"Minimal residual disease detection by next-generation sequencing in multiple myeloma: Promise and challenges for response-adapted therapy","volume":"12","author":"Ferla V, Antonini E, Perini T, Farina F, Masottini S, Malato S","year":"2022","unstructured":"84. Ferla V, Antonini E, Perini T, Farina F, Masottini S, Malato S, Minimal residual disease detection by next-generation sequencing in multiple myeloma: Promise and challenges for response-adapted therapy, Front Oncol, 2022;12932852","journal-title":"Front Oncol"},{"issue":"10","key":"ref85","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1038\/leu.2017.29","article-title":"Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma","volume":"31","author":"Flores-Montero J, Sanoja-Flores L, Paiva B, Puig N, Garc\u00eda-S\u00e1nchez O, B\u00f6ttcher S","year":"2017","unstructured":"85. Flores-Montero J, Sanoja-Flores L, Paiva B, Puig N, Garc\u00eda-S\u00e1nchez O, B\u00f6ttcher S, Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma, Leukemia, 2017;31(10):2094-103","journal-title":"Leukemia"},{"issue":"14","key":"ref86","doi-asserted-by":"publisher","first-page":"3687","DOI":"10.3390\/cancers15143687","article-title":"Minimal Residual Disease in Multiple Myeloma: Past, Present, and Future","volume":"15","author":"Medina-Herrera A, Sarasquete ME, Jim\u00e9nez C, Puig N, Garc\u00eda-Sanz R","year":"2023","unstructured":"86. Medina-Herrera A, Sarasquete ME, Jim\u00e9nez C, Puig N, Garc\u00eda-Sanz R, Minimal Residual Disease in Multiple Myeloma: Past, Present, and Future, Cancers (Basel), 2023;15(14):3687","journal-title":"Cancers (Basel)"},{"issue":"3","key":"ref87","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1111\/bjh.18249","article-title":"Minimal residual disease and imaging-guided consolidation strategies in newly diagnosed and relapsed refractory multiple myeloma","volume":"198","author":"B\u00f6ckle D, Tabares P, Zhou X, Schimanski S, Steinhardt MJ, Bittrich M","year":"2022","unstructured":"87. B\u00f6ckle D, Tabares P, Zhou X, Schimanski S, Steinhardt MJ, Bittrich M, Minimal residual disease and imaging-guided consolidation strategies in newly diagnosed and relapsed refractory multiple myeloma, Br J Haematol, 2022;198(3):515-522","journal-title":"Br J Haematol"},{"issue":"6","key":"ref88","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.jmoldx.2015.05.007","article-title":"Minimal Residual Disease Detection by Droplet Digital PCR in Multiple Myeloma, Mantle Cell Lymphoma, and Follicular Lymphoma: A Comparison with Real-Time PCR","volume":"17","author":"Drandi D, Kubiczkova-Besse L, Ferrero S, Dani N, Passera R, Mantoan B","year":"2015","unstructured":"88. Drandi D, Kubiczkova-Besse L, Ferrero S, Dani N, Passera R, Mantoan B, Minimal Residual Disease Detection by Droplet Digital PCR in Multiple Myeloma, Mantle Cell Lymphoma, and Follicular Lymphoma: A Comparison with Real-Time PCR, J Mol Diagn, 2015;17(6):652-60","journal-title":"J Mol Diagn"},{"issue":"8","key":"ref89","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P","year":"2016","unstructured":"89. Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma, Lancet Oncol, 2016;17(8):e328-46","journal-title":"Lancet Oncol"}],"container-title":["Journal of Medicine and Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/medandlife.org\/all-issues\/2025\/issue-6-2025\/review-issue-6-2025\/beyond-the-bone-marrow-a-review-of-therapeutic-approaches-for-extramedullary-disease-in-multiple-myeloma-and-the-significance-of-mrd-assessment\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T13:59:36Z","timestamp":1763387976000},"score":1,"resource":{"primary":{"URL":"https:\/\/medandlife.org\/all-issues\/2025\/issue-6-2025\/review-issue-6-2025\/beyond-the-bone-marrow-a-review-of-therapeutic-approaches-for-extramedullary-disease-in-multiple-myeloma-and-the-significance-of-mrd-assessment\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":89,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["JMedLife-18-536"],"URL":"https:\/\/doi.org\/10.25122\/jml-2025-0104","relation":{},"ISSN":["1844-3117"],"issn-type":[{"value":"1844-3117","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6]]}}}